期刊
EPIGENETICS
卷 10, 期 8, 页码 736-748出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15592294.2015.1062206
关键词
cancer germline genes; cancer testis antigen genes; CT45; decitabine; DNA methylation; epithelial ovarian cancer; tumor antigens
资金
- Otis Glebe Medical Research Foundation
- Betty J. and Charles D. McKinsey Ovarian Cancer Research Fund
- Fred & Pamela Buffett Cancer Center
- Roswell Park Alliance Foundation
- NCI Cancer Center Support Grant [P30CA016056, NIHR01CA158318]
- RPCI-UPCI Ovarian Cancer SPORE [P50CA159981, NIHT32CA009476, NIHT32CA108456]
- [NIH-RO1CA116674]
Epithelial ovarian cancer (EOC) is a highly lethal malignancy due to a lack of early detection approaches coupled with poor outcomes for patients with clinically advanced disease. Cancer-testis (CT) or cancer-germline genes encode antigens known to generate spontaneous anti-tumor immunity in cancer patients. CT45 genes are a recently discovered 6-member family of X-linked CT genes with oncogenic function. Here, we determined CT45 expression in EOC and fully defined its epigenetic regulation by DNA methylation. CT45 was silent and hypermethylated in normal control tissues, but a large subset of EOC samples showed increased CT45 expression in conjunction with promoter DNA hypomethylation. In contrast, copy number status did not correlate with CT45 expression in the TCGA database for EOC. CT45 promoter methylation inversely correlated with both CT45 mRNA and protein expression, the latter determined using IHC staining of an EOC TMA. CT45 expression was increased and CT45 promoter methylation was decreased in late-stage and high-grade EOC, and both measures were associated with poor survival. CT45 hypomethylation was directly associated with LINE-1 hypomethylation, and CT45 was frequently co-expressed with other CT antigen genes in EOC. Decitabine treatment induced CT45 mRNA and protein expression in EOC cells, and promoter transgene analyses indicated that DNA methylation directly represses CT45 promoter activity. These data verify CT45 expression and promoter hypomethylation as possible prognostic biomarkers, and suggest CT45 as an immunological or therapeutic target in EOC. Treatment with decitabine or other epigenetic modulators could provide a means for more effective immunological targeting of CT45.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据